CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
CIViC Variants/G12D

G12D

CIViC ID: 79 · Gene: KRAS

Variant Summary

Also known as
GLY12ASP,RS121913529
HGVS
NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A
Variant Type(s)
missense_variant
Evidence Items
21

Evidence Level Distribution

Level B: 7Level C: 7Level D: 7

Evidence Items

Showing CIViC evidence rows where gene = KRAS and variant = G12D.

LevelTypeDirectionSignificanceDiseaseDrugsRating
BPrognosticSupportsPoor OutcomePancreatic Cancer4
DPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,Dactolisib4
BPrognosticSupportsBetter OutcomeColorectal Cancer3
BPrognosticSupportsPoor OutcomeMalignant Exocrine Pancreas Neoplasm3
BPrognosticSupportsPoor OutcomePancreatic Ductal Carcinoma3
CPredictiveSupportsSensitivity/ResponseColorectal CancerTherapeutic Tumor Infiltrating Lymphocytes3
CPredictiveSupportsResistanceColorectal CancerPanitumumab3
BPredictiveSupportsResistanceColorectal CancerCetuximab3
DPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,Dactolisib3
BDiagnosticSupportsPositiveLung Cancer3
DPredictiveSupportsResistanceOvarian CancerCetuximab3
CPredictiveSupportsResistanceHairy Cell LeukemiaVemurafenib2
BPredictiveSupportsResistanceLung CancerGefitinib2
DPredictiveSupportsResistanceMultiple MyelomaMelphalan2
DPredictiveSupportsResistanceMultiple MyelomaMelphalan2
CPredictiveSupportsResistanceColorectal CancerPanitumumab,Cetuximab2
CPredictiveSupportsResistanceLung AdenocarcinomaDabrafenib2
CPredictiveSupportsSensitivity/ResponsePancreatic CarcinomaAkt Inhibitor MK22062
DPredictiveSupportsResistanceColorectal CancerRegorafenib Anhydrous1
CPredictiveSupportsResistanceColorectal CancerPanitumumab0
DPredictiveSupportsResistanceMultiple MyelomaMelphalan0